2017 annual financial data
CRISPR Therapeutics 2017 Net margin
CRISPR Therapeutics 2017 net margin with verified reported values.
Direct answer
Net margin was -166.74%.
Operating income was -64,648,000 USD and net income was -68,357,000 USD.
Operating cash flow was -70,097,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 40,997,000 USD
- Operating income
- -64,648,000 USD
- Net income
- -68,357,000 USD
- Operating cash flow
- -70,097,000 USD